RBI
ESPR

Raiffeisen Bank International’s Esperion Therapeutics ESPR Stock Holding History

Raiffeisen Bank International’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9K Hold
4,400
– – ﹤0.01% 690
2026
Q1 		$12.1K Hold
4,400
– – ﹤0.01% 722
2025
Q4 		$13.7K Hold
4,400
– – ﹤0.01% 689
2025
Q3 		$11.7K Buy
+4,400
New +$8.51K ﹤0.01% 735

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $490M AUM 21.68% 1-Year Est. Return

Raiffeisen Bank International's ESPR Position: Q3 2025 in Review

Raiffeisen Bank International sold out of Esperion Therapeutics (ESPR) in Q3 2025, closing a stake of 4,400 shares — an estimated $8.51K sold.

Raiffeisen Bank International first reported a position in ESPR in Q4 2024 and held it in 3 quarters. The position peaked at $9.92K in Q4 2024. 188 funds tracked by Wall St. Rank hold ESPR as of Q3 2025.

  • Raiffeisen Bank International reported no remaining Esperion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raiffeisen Bank International sold 4,400 Esperion Therapeutics shares in Q3 2025, an estimated $8.51K.
  • Raiffeisen Bank International first reported a position in Esperion Therapeutics in Q4 2024 and held it in 3 quarters.
  • Raiffeisen Bank International's Esperion Therapeutics position peaked at $9.92K in Q4 2024.
  • 188 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2025.

Based on Raiffeisen Bank International's 13F filing for Q3 2025, filed 10 Nov 2025.